UroGen Pharma: An Emerging GARP Stock
UroGen Pharma (URGN) stock dipped 30% after a 208% rally—see why Zusduri’s launch, reimbursement, and patents could fuel ...
Model output · Signal date 2026-10-14
Urogen Pharma Ltd. (URGN) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 5379 stocks scored
Rank correlation · 90D
n/a
No per-ticker sample yet
Market Cap
$1.87B
small-cap · #60 of 60 peers
Summary
Urogen Pharma Ltd. (URGN) stock forecast summary
Our AI ranks Urogen Pharma Ltd. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Urogen Pharma Ltd. is a small-cap company with a market capitalization of $1.87B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for URGN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, URGN included.
Follow URGN freePrice
URGN price chart and AI forecast
Cross-section · 2026-10-14
How URGN ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals
Urogen Pharma Ltd. (URGN) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | URGN | Rank |
|---|---|---|
| Market Cap | $1.87B | 60/60 |
| Revenue/Share | $3.86 | – |
| FCF/Share | $-3.26 | – |
Profitability & Margins
| Metric | URGN | Rank |
|---|---|---|
| ROA | -38.6% | 32/39 |
| ROIC | -35.0% | 30/41 |
| Gross Margin | 91.8% | 6/29 |
| Operating Margin | -35.3% | 24/33 |
| Net Margin | -51.7% | 25/33 |
| EBT Margin | -52.0% | 32/40 |
| Tax Rate | 0.5% | – |
Financial Health
| Metric | URGN | Rank |
|---|---|---|
| Current Ratio | 3.80x | 19/50 |
| Quick Ratio | 3.41x | 7/37 |
| Interest Coverage | -18.7x | 27/36 |
| Working Capital | $174M | 48/50 |
Cash Flow
| Metric | URGN | Rank |
|---|---|---|
| Operating Cash Flow | -$159M | 37/49 |
| Free Cash Flow | -$159M | 28/39 |
| Capital Spending | -$220K | 2/39 |
| FCF/Sales | -84.3% | 31/34 |
| CapEx/Sales | 0.1% | 32/34 |
Operational Efficiency
| Metric | URGN | Rank |
|---|---|---|
| Asset Turnover | 0.75x | 6/38 |
| Receivables Turnover | 2.1x | 33/34 |
| Inventory Turnover | 0.6x | 23/27 |
| Fixed Assets Turnover | 316.1x | 4/37 |
| Days Sales Outstanding | 172 days | 2/34 |
| Days Inventory | 580 days | 5/27 |
| Payables Period | 365 days | 6/23 |
| Cash Conversion Cycle | 387 days | 5/21 |
Income Statement
| Metric | URGN | Rank |
|---|---|---|
| Total Revenue | $188M | 37/39 |
| Operating Income | -$66M | 22/41 |
| Net Income | -$97M | 23/40 |
| R&D Expense | $61M | 45/48 |
| SG&A Expense | $177M | 34/35 |
| Cost of Goods Sold | $15M | 25/27 |
Dividend & Shareholder Information
| Metric | URGN | Rank |
|---|---|---|
| Shares Outstanding | 49M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $235M | |
| Cash & Short-term Investments | $79M | |
| Accounts Receivable | $89M | |
| Inventory | $25M | |
| Total Liabilities | $385M | |
| Short-term Debt | $46M |
Quarterly Financial Reports
URGN quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Urogen Pharma Ltd. (URGN) industry peers
Companies classified under the same SEC industry code as Urogen Pharma Ltd. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| URGN Urogen Pharma Ltd. | ▲ | $1.87B |
| LLY Eli Lilly & Co | ▲ | $1.10T |
| JNJ Johnson & Johnson | ▼ | $599.12B |
| ONC Beone Medicines Ltd. | ▶ | $515.98B |
| ABBV Abbvie Inc. | ▼ | $484.83B |
| MRK Merck & Co., Inc. | ▼ | $350.29B |
| NVS Novartis Ag | ▼ | $271.74B |
| GSK Gsk Plc | ▼ | $199.68B |
| ABT Abbott Laboratories | ▶ | $178.73B |
| PFE Pfizer Inc | ▲ | $161.70B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $122.98B |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $77.54B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $48.07B |
| SNY Sanofi | ▼ | $47.70B |
| RPRX Royalty Pharma Plc | ▲ | $32.53B |
| ZTS Zoetis Inc. | ▼ | $30.70B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.46B |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.01B |
| ZLAB Zai Lab Ltd | ▼ | $25.93B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.09B |
| UTHR United Therapeutics Corp | ▼ | $23.31B |
| INSM Insmed Inc | ▶ | $21.14B |
| VTRS Viatris Inc | ▶ | $19.81B |
| ASND Ascendis Pharma A/S | ▶ | $13.83B |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $13.66B |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.38B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.37B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.25B |
| HCM Hutchmed (China) Ltd | ▶ | $11.78B |
| ELAN Elanco Animal Health Inc | ▶ | $11.20B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.66B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.45B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.96B |
| CYTK Cytokinetics Inc | ▶ | $8.57B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.09B |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.04B |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $6.79B |
| ABVX Abivax S.A. | ▼ | $6.77B |
| ALKS Alkermes Plc. | ▶ | $6.67B |
| LEGN Legend Biotech Corp | ▶ | $6.61B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.05B |
| BLTE Belite Bio, Inc | ▲ | $5.97B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.96B |
| BLRX Biolinerx Ltd. | ▶ | $5.67B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.17B |
| ERAS Erasca, Inc. | ▲ | $5.17B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.00B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.88B |
| COGT Cogent Biosciences, Inc. | ▼ | $4.87B |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B |
| MANE Veradermics, Inc | ▲ | $4.86B |
| GPCR Structure Therapeutics Inc. | ▲ | $4.77B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B |
Where URGN sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Urogen Pharma Ltd. (URGN) stock news
UroGen Pharma Officer Christopher Degnan Files Rule 144 to Sell 2,202 Shares for Tax Withholding
Seller: Christopher Degnan, officer at UroGen Pharma Ltd., is the beneficial owner initiating the sale. Shares for sale: ...
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q3 2021 Results - Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q3 2021 Earnings Conference Call November 15, 2021, 10:00 AM ET Company Participants Lee Roth - IR Liz Barrett - President and CEO ...
FAQ
Urogen Pharma Ltd. (URGN) stock forecast FAQ
What is the Urogen Pharma Ltd. (URGN) stock forecast?
Our AI ranks Urogen Pharma Ltd. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Urogen Pharma Ltd. stock predictions?
A per-ticker accuracy statistic for URGN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Urogen Pharma Ltd. forecasts updated?
Urogen Pharma Ltd. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Urogen Pharma Ltd.'s industry peers?
60 issuers in our coverage, URGN included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.